by Primrose Bio | Nov 10, 2025 | Featured, Press
Maximize capping efficiency and minimize double-stranded RNA (“dsRNA”) in the manufacturing of self-amplifying mRNA San Diego, Calif. Nov. 10, 2025 – Primrose Bio, Inc. (“Primrose”), a company with proprietary therapeutic manufacturing technologies, today announced... 
by Primrose Bio | Oct 1, 2025 | Featured, Press
San Diego, Calif. October 1, 2025 – Primrose Bio, Inc. (“Primrose”) announced today the appointment of Andrew “Drew” Burch as its Chief Executive Officer, and member of the Board of Directors. Drew succeeds Helge Zieler, PhD, who will move into a new role of Chief... 
by Primrose Bio | Mar 26, 2025 | Featured, Press
Significantly increased quality and lower manufacturing costs for long template mRNAs San Diego, Calif. March 26, 2025 – Primrose Bio, Inc. (“Primrose”), a company developing proprietary therapeutic manufacturing technologies, announces the launch of Prima RNApols™... 
by Primrose Bio | Jan 10, 2025 | Featured, Press
Primrose Bio, Inc. (“Primrose”), a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt. Ltd. (“SIIPL”), the world’s largest vaccine manufacturer, today announced a collaboration to develop a novel multi-antigen... 
by Primrose Bio | Sep 3, 2024 | Featured, Press
Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced... 
by Primrose Bio | Jun 17, 2024 | Featured, Press
Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a...